During human prostate cancer development, GATA3 mRNA levels are found to be significantly reduced in primary prostate tumors [30, 52], in contrast to GATA2 whose mRNA levels are unchanged in primary prostate tumors and moderately increased in metastatic prostate tumors [30, 52]. This evidence concerns the gene GATA3 and prostate carcinoma.